OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
6
Results
Show all
Save search
Copy query
Show results for
Unknown
(6)
Publication Date
Release Date
2021
(3)
2025
(2)
2022
(1)
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data.
Not available
S-EPMC8518716
|
biostudies-literature
Cite
Exploratory digital outcome measures of motor sign progression in Parkinson's disease patients treated with prasinezumab.
Not available
S-EPMC12170883
|
biostudies-literature
Cite
Time-to-event analysis mitigates the impact of symptomatic therapy on therapeutic benefit in Parkinson's disease trials.
Not available
S-EPMC12214479
|
biostudies-literature
Cite
Statistical biases due to anonymization evaluated in an open clinical dataset from COVID-19 patients.
Not available
S-EPMC9769467
|
biostudies-literature
Cite
Hoehn and Yahr Stage and Striatal Dat-SPECT Uptake Are Predictors of Parkinson's Disease Motor Progression.
Not available
S-EPMC8711238
|
biostudies-literature
Cite
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.
Not available
S-EPMC7787219
|
biostudies-literature
Cite
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets